Portage Biotech (NASDAQ:ALP – Get Free Report) and VivoPower PLC Ordinary Shares (NASDAQ:VIVO – Get Free Report) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.
Profitability
This table compares Portage Biotech and VivoPower PLC Ordinary Shares’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Portage Biotech | N/A | N/A | N/A |
| VivoPower PLC Ordinary Shares | N/A | N/A | N/A |
Insider and Institutional Ownership
13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 15.8% of VivoPower PLC Ordinary Shares shares are owned by institutional investors. 2.3% of VivoPower PLC Ordinary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Portage Biotech | $100,000.00 | 36.26 | -$38.63 million | ($8.18) | -0.02 |
| VivoPower PLC Ordinary Shares | $60,000.00 | 910.51 | -$12.79 million | N/A | N/A |
VivoPower PLC Ordinary Shares has lower revenue, but higher earnings than Portage Biotech.
Risk and Volatility
Portage Biotech has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, VivoPower PLC Ordinary Shares has a beta of -0.7, suggesting that its share price is 170% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Portage Biotech and VivoPower PLC Ordinary Shares, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
| VivoPower PLC Ordinary Shares | 1 | 0 | 1 | 0 | 2.00 |
Portage Biotech presently has a consensus price target of $0.25, suggesting a potential upside of 61.81%. VivoPower PLC Ordinary Shares has a consensus price target of $10.00, suggesting a potential upside of 129.36%. Given VivoPower PLC Ordinary Shares’ stronger consensus rating and higher probable upside, analysts plainly believe VivoPower PLC Ordinary Shares is more favorable than Portage Biotech.
Summary
VivoPower PLC Ordinary Shares beats Portage Biotech on 7 of the 9 factors compared between the two stocks.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
About VivoPower PLC Ordinary Shares
VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
